A boy's temperature is taken using an infrared digital laser thermometer at the Nnamdi Azikiwe International Airport in Abuja, August 11, 2014. Nigeria's commercial capital Lagos has 10 confirmed cases of Ebola, up from seven at the last count, and two patients have died, including the Liberian who brought the virus in, the health minister said on Monday. Photo: Reuters/Afolabi Sotunde
Geneva: The World Health Organisation authorised the use of experimental drugs in the fight against Ebola on Tuesday as the death toll topped 1,000 and a Spanish priest became the first European to succumb to the latest outbreak of the virus.
The declaration by the UN's health agency came after a US company that makes an experimental serum said it had sent all its available supplies to hard-hit west Africa.
"In the particular circumstances of this outbreak, and provided certain conditions are met... it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects," the WHO said in a statement following a teleconference between medical experts.
More than 1,000 killed
The current outbreak, described as the worst since Ebola was first discovered four decades ago, has now killed 1,013 people since early this year, the WHO said.
Cases have so far been limited to Guinea, Liberia, Sierra Leone and Nigeria, all in west Africa where ill-equipped and fragile health systems are struggling to cope.
Elderly Spanish priest Miguel Pajares, who became infected while helping patients in Liberia died in a Madrid hospital on Tuesday, five days after being evacuated.
Monrovia said it had requested samples of an experimental drug, ZMapp, that has shown some positive effects on two US aid workers but failed to save the Spanish priest.
Supplies would be brought in by a representative of the US government later this week, the Liberian government said.
There is currently no available cure or vaccine for Ebola, which the WHO has declared a global public health emergency, and the use of experimental drugs has stoked an ethical debate.
Despite promising results for the ZMapp treatment, made by private US company Mapp Biopharmaceutical, it is still in an early phase of development and had only been tested previously on monkeys.
ZMapp is in very short supply, but its use on the Western aid workers evacuated to the United States last week triggered controversy and demands that it be made available in Africa.
The company did not reveal which nation received the doses, or how many were sent.
But the Liberian presidency said: "The White House and the United States Food and Drug Administration have approved the request for sample doses of experimental serum to treat Liberian doctors who are currently infected with the deadly Ebola virus disease."
Eight Chinese medical workers who treated patients with Ebola have been placed in quarantine in Sierra Leone, Beijing's ambassador said on Monday, but would not be drawn on whether they were displaying symptoms of the disease.